Compound
Berberine
Preliminary EvidenceCompound
Hermetica Superfood Encyclopedia
Berberine is a quaternary isoquinoline alkaloid that exerts its primary pharmacological effects through activation of AMP-activated protein kinase (AMPK), modulation of NF-κB/MAPK inflammatory signaling, inhibition of PCSK9, and direct antimicrobial activity against a broad spectrum of pathogens. In clinical studies involving patients with type 2 diabetes and metabolic syndrome, berberine at 500 mg three times daily has demonstrated reductions in fasting blood glucose, HbA1c, LDL cholesterol, and triglycerides comparable in magnitude to standard pharmaceutical agents such as metformin, alongside documented antidiarrheal and anti-infective efficacy in acute gastroenteritis.
Berberine is a naturally occurring isoquinoline alkaloid found in the roots, rhizomes, and stem bark of several plant species distributed across Asia, Europe, and North America, including Coptis chinensis (goldthread, native to China and Japan), Berberis vulgaris (barberry, widespread across Europe and western Asia), and Phellodendron amurense (Amur cork tree, native to northeastern China and Russia). The plants thrive in temperate to subtropical climates, typically in moist, well-drained soils at moderate to high altitudes, and have been cultivated in China for millennia specifically for medicinal root harvests. Berberine concentration in raw plant material typically ranges from 0.5% to 8% by dry weight depending on species, plant part, growing conditions, and extraction methodology, with Coptis chinensis roots yielding among the highest concentrations (up to 5–8%).
Berberine is among the more robustly studied botanical compounds in metabolic medicine, with a body of evidence comprising multiple randomized controlled trials (RCTs), systematic reviews, and meta-analyses, though most individual trials are small to moderate in size (typically 30–200 participants) and of short duration (8–24 weeks), largely conducted in Chinese clinical populations, which limits generalizability. Several meta-analyses have pooled data from RCTs in type 2 diabetes and dyslipidemia, finding statistically significant reductions in fasting blood glucose, HbA1c, LDL cholesterol, and triglycerides at standard doses of 500 mg three times daily, with effect sizes frequently described as comparable to metformin or statins in head-to-head comparisons, though methodological heterogeneity across trials warrants cautious interpretation. For its primary traditional indication of antidiarrheal and anti-infective use in gastroenteritis, controlled clinical data are more limited in volume, but existing trials and pharmacological mechanistic data support its efficacy against common enteropathogens. Preclinical evidence is extensive and mechanistically compelling across metabolic, neurological, cardiovascular, and oncological domains, but robust large-scale, multi-center RCTs with pre-registered protocols and diverse populations are still needed to fully validate clinical claims beyond metabolic indications.
Berberine is a pure alkaloid compound rather than a whole food, and as an isolated molecule it does not provide meaningful macronutrients (protein, fat, or carbohydrate) or micronutrients (vitamins or minerals) in supplemental doses. The compound itself is a quaternary ammonium salt with molecular formula C₂₀H₁₈NO₄⁺ and a distinctive bright yellow color derived from its conjugated ring system; its pharmacological activity is entirely attributable to this alkaloid structure rather than nutritional content. In the whole plants from which it is derived (Coptis chinensis, Berberis vulgaris), additional phytochemicals are present including related isoquinoline alkaloids (palmatine, coptisine, epiberberine, jateorhizine) that may contribute minor complementary pharmacological activity, though berberine dominates at 50–90% of total alkaloid content in standardized extracts. Oral bioavailability of free berberine is notably poor (estimated at under 5%) due to efflux by intestinal P-glycoprotein, rapid phase I/II hepatic metabolism, and gut microbiota biotransformation to dihydroberberine and other metabolites; notably, dihydroberberine may itself contribute to systemic AMPK activation after intestinal reabsorption.
Berberine's primary mechanism centers on allosteric and indirect activation of AMP-activated protein kinase (AMPK) — the cellular master energy sensor — which triggers downstream phosphorylation events that increase GLUT4 translocation to cell membranes, inhibit acetyl-CoA carboxylase (ACC) to reduce fatty acid synthesis, suppress SREBP-1c-mediated lipogenesis, and inhibit hepatic gluconeogenesis by reducing expression of PEPCK and G6Pase. Simultaneously, berberine intercalates into DNA and inhibits the NF-κB transcription factor complex and MAPK (ERK, JNK, p38) signaling cascades, suppressing transcription of pro-inflammatory cytokines (IL-1β, IL-6, TNF-α) and upregulating the Nrf2/Keap1 antioxidant response element to increase cytoprotective enzymes HO-1, SOD, CAT, and GPx while reducing reactive oxygen species and lipid peroxidation byproduct MDA. Berberine also post-transcriptionally inhibits PCSK9 protein secretion, preserving hepatic LDL receptor recycling and reducing circulating LDL, and directly disrupts microbial cell membranes and inhibits bacterial topoisomerase II (DNA gyrase) to exert its antimicrobial actions. Additional molecular targets include modulation of the PI3K/AKT/mTOR pathway (upregulating pro-apoptotic BAX and caspases while downregulating anti-apoptotic BCL2 in tumor models), enhancement of SIRT1–PGC-1α mitochondrial biogenesis signaling, and ferroptosis suppression through Nrf2-mediated upregulation of SLC7A11 and GPX4.
The most clinically replicated findings for berberine involve metabolic outcomes: multiple RCTs and their meta-analyses report that berberine 500 mg three times daily over 8–24 weeks significantly reduces fasting plasma glucose (by approximately 20–30 mg/dL in diabetic populations), HbA1c (by approximately 0.7–1.0 percentage points), LDL cholesterol, and triglycerides in patients with type 2 diabetes or metabolic syndrome, with effect sizes broadly comparable to metformin in direct comparisons. For antidiarrheal and anti-infective indications — its primary traditional and early modern clinical application — controlled studies in infectious diarrhea, including those caused by Vibrio cholerae and enterotoxigenic E. coli, have demonstrated reduced stool volume, shortened illness duration, and pathogen clearance, though this evidence base is older and smaller in scale than the metabolic literature. Anti-inflammatory, cardiovascular, and neuroprotective benefits are primarily supported by preclinical mechanistic studies and early-phase human data, with insufficient large RCT evidence to make quantitative efficacy claims. Overall clinical confidence for metabolic applications is moderate to moderately strong, while confidence for other indications remains preliminary, pending larger, more rigorous trials.
At typical supplemental doses of 500 mg two to three times daily, berberine is generally well tolerated, with the most commonly reported adverse effects being gastrointestinal in nature — including nausea, cramping, diarrhea, and constipation — which tend to be mild, dose-dependent, and reduced by taking the compound with food; prolonged use may alter gut microbiota composition, with clinical implications that are not yet fully characterized. Berberine is a clinically significant inhibitor of cytochrome P450 enzymes CYP2D6, CYP2C9, and CYP3A4, as well as P-glycoprotein and organic cation transporters, which can elevate plasma concentrations of co-administered drugs including cyclosporine, warfarin, certain statins, macrolide antibiotics, antiarrhythmics (particularly those with QT-prolongation risk such as amiodarone), and antidiabetic agents; co-administration with blood glucose-lowering drugs (metformin, sulfonylureas, insulin) warrants caution due to additive hypoglycemic risk. Berberine is contraindicated in pregnancy because it crosses the placental barrier and has demonstrated uterine-stimulating activity and potential fetal toxicity (including neonatal jaundice risk via inhibition of bilirubin clearance) in both animal studies and historical case reports; it should also be avoided during lactation as it is excreted in breast milk. No established regulatory maximum safe dose exists for adults, but most clinical trials have not exceeded 1,500 mg/day total, and doses above this threshold have not been adequately evaluated for long-term safety in controlled human studies.
7 documented interactions for Berberine. Click any row to read the full explanation. Always consult your healthcare provider before combining supplements with medications.
Both Berberine and Glucotrol lower blood sugar aggressively. Together the risk of dangerous lows is high.
What to do: Monitor your blood sugar more frequently. Keep fast-acting glucose (juice, glucose tablets) nearby. Report any symptoms of low blood sugar: shakiness, sweating, confusion, rapid heartbeat.
Timing: Several botanicals have glucose-lowering properties (berberine, bitter melon, cinnamon, fenugreek, gymnema). If Berberine is one of these, monitor blood sugar closely — additive hypoglycemia is possible. Take Glipizide with meals as prescribed. The botanical can be taken at a separate meal.
Full interaction details →Berberine powerfully lowers blood sugar. Adding to insulin without dose adjustment risks dangerous hypoglycemia.
What to do: Monitor your blood sugar more frequently. Keep fast-acting glucose (juice, glucose tablets) nearby. Report any symptoms of low blood sugar: shakiness, sweating, confusion, rapid heartbeat.
Timing: Several botanicals have glucose-lowering properties (berberine, bitter melon, cinnamon, fenugreek, gymnema). If Berberine is one of these, monitor blood sugar closely — additive hypoglycemia is possible. Take Insulin (all forms) with meals as prescribed. The botanical can be taken at a separate meal.
Full interaction details →Berberine slows how your body processes Lipitor, potentially increasing statin side effects like muscle pain.
What to do: Berberine can affect how your body processes Atorvastatin. Your doctor may need to monitor drug levels or adjust doses of Atorvastatin while you're also taking Berberine.
Timing: Take Atorvastatin in the evening when hepatic cholesterol synthesis peaks (exception: atorvastatin and rosuvastatin have long half-lives and can be taken any time). Berberine can be taken at a separate meal. Avoid St. John's Wort (reduces statin levels via CYP3A4 induction) and grapefruit extract (increases levels). Report any unexplained muscle pain or weakness.
Full interaction details →Berberine may increase Zocor levels in your blood, raising risk of muscle side effects.
What to do: Berberine can affect how your body processes Simvastatin. Your doctor may need to monitor drug levels or adjust doses of Simvastatin while you're also taking Berberine.
Timing: Take Simvastatin in the evening when hepatic cholesterol synthesis peaks (exception: atorvastatin and rosuvastatin have long half-lives and can be taken any time). Berberine can be taken at a separate meal. Avoid St. John's Wort (reduces statin levels via CYP3A4 induction) and grapefruit extract (increases levels). Report any unexplained muscle pain or weakness.
Full interaction details →Berberine may affect how Warfarin works. If taking both, monitor INR closely.
What to do: Berberine can affect how your body processes Warfarin. Your doctor may need to monitor drug levels or adjust doses of Warfarin while you're also taking Berberine.
Timing: Use caution. Many botanicals affect blood clotting — ginkgo, garlic, ginger, turmeric, and dong quai all have antiplatelet activity that can amplify Warfarin. St. John's Wort can REDUCE anticoagulant effectiveness. Take at separate times and inform your prescriber about all herbal supplements. Request more frequent INR monitoring if on warfarin.
Full interaction details →Berberine works like natural Metformin. Taking both could drop blood sugar too low. If combining, start with half doses.
What to do: When starting Berberine alongside Metformin, monitor your blood sugar more frequently. This combination may actually be beneficial at controlled doses — discuss the optimal approach with your doctor.
Timing: Several botanicals have glucose-lowering properties (berberine, bitter melon, cinnamon, fenugreek, gymnema). If Berberine is one of these, monitor blood sugar closely — additive hypoglycemia is possible. Take Metformin with meals as prescribed. The botanical can be taken at a separate meal.
Full interaction details →Berberine can slow Flexeril processing, potentially increasing drowsiness and side effects.
What to do: Berberine can affect how your body processes Cyclobenzaprine. Your doctor may need to monitor drug levels or adjust doses of Cyclobenzaprine while you're also taking Berberine.
Timing: Take Cyclobenzaprine as prescribed. Berberine can typically be taken with a meal at a different time. As a general rule, space botanicals 1-2 hours from prescription medications. St. John's Wort is the most interaction-prone botanical — it affects dozens of drugs via CYP enzyme induction. Always inform your prescriber about herbal supplements.
Full interaction details →Educational information only. Always consult a qualified healthcare provider before changing your supplement or medication regimen.
